SkylineDX BV

Disease often harbors genomic changes in the cells. By measuring these genomic alterations, we can have a better understanding of how the disease will develop over time. With more information available on the course of the disease, care providers can set out a more personalized treatment path, offering the patient a better quality of life.

To facilitate our mission, we are continuously improving the world of gene signature-based (genomic) diagnostic testing. Our story is one of passion, innovation, and dedication. Founded with a vision to personalize healthcare through state-of-the-art diagnostics, we have cultivated a culture that thrives on collaboration, integrity, and relentless pursuit of excellence.

Historically and generally, patients with the same type of disease are treated the same. Despite knowing that a group of patients will respond less or not respond at all. In oncology, inflammatory diseases, and many other indications, the large clinical unmet need is identifying upfront who will respond and who will not. Who will need surgical intervention and who does not. Knowing this prior to treatment saves debilitating side effects, additional hospitalizations, complications, medication and medical interventions, and, ultimately, a worse quality of life.

Luckily, recent decades have shown vast research interest in finding biomarkers that can classify a patient as responder versus non-responder, at high risk for developing metastasis versus at low risk or at high risk of having a specific disease or to rule out disease. These biomarkers have a pivotal role in addressing the clinical unmet need.

At SkylineDx, it is our aim to translate this biomarker research into a tangible test (molecular assay) that fulfills all criteria for safe use in the clinic. Ultimately, it supports care providers and patients in decision-making on whether a therapy will work or surgery is necessitated.